BTTX (Better Therapeutics) Ending Cash Position: $6.60 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Better Therapeutics Ending Cash Position?

Better Therapeutics BTTX Ending Cash Position is $6.60 Mil as of Sep. 2023.

Better Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2023 was $6.60 Mil.

Better Therapeutics's quarterly Ending Cash Position increased from Mar. 2023 ($6.07 Mil) to Jun. 2023 ($6.20 Mil) and increased from Jun. 2023 ($6.20 Mil) to Sep. 2023 ($6.60 Mil).

Better Therapeutics's annual Ending Cash Position increased from Dec. 2020 ($0.12 Mil) to Dec. 2021 ($40.57 Mil) but then declined from Dec. 2021 ($40.57 Mil) to Dec. 2022 ($15.74 Mil).

Better Therapeutics Ending Cash Position Related Terms

Better Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Better Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Better Therapeutics Ending Cash Position Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Ending Cash Position
0.76 0.12 40.57 15.74

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.31 15.74 6.07 6.20 6.60

Better Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Better Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=40.566+-24.826
=15.74

Better Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.196+0.402
=6.60

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6.60 Mil mean?
Better Therapeutics (BTTX) has a Ending Cash Position of $6.60 Mil as of Sep. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Better Therapeutics and its competitors.
Is Better Therapeutics' Ending Cash Position too high?
Better Therapeutics' current Ending Cash Position is $6.60 Mil.
How does Better Therapeutics' Ending Cash Position compare to CYCN and CELZ?
Better Therapeutics' Ending Cash Position of $6.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Better Therapeutics and its competitors. Better Therapeutics's current Ending Cash Position is $6.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Better Therapeutics stock overvalued right now?
Better Therapeutics (BTTX) has a current Ending Cash Position of $6.60 Mil. The current Ending Cash Position is $6.60 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Better Therapeutics (BTTX), the current Ending Cash Position is $6.60 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Better Therapeutics Business Description

Address 548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.